Subscribe To
IQAIF / IQ-AI notes positive outcomes from recent pediatric brain tumour studies
IQAIF News
By Proactive Investors
October 18, 2023
IQ-AI higlights use of subsidiary's software in brain cancer study
IQ-AI has highlighted a new study into a rare form of brain cancer that used subsidiary Imaging Biometric's dynamic susceptibility contrast (DSC) ma more_horizontal
By Proactive Investors
October 9, 2023
IQ-AI subsidairy secures second orphan drug designation
IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF)'s subsidiary, Imaging Biometrics, has secured orphan drug designation from the US Food and Drug Administration for more_horizontal
By Proactive Investors
September 8, 2023
IQ-AI hails the latest data on IB Neuro technology
Imaging Biometrics (IB), a subsidiary of IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF), has confirmed the effectiveness of its IB Neuro technology for brain scan more_horizontal
By Proactive Investors
August 17, 2023
IQ-AI to focus on the commercial potential of its software alongside phase I study
IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF) said it aims to convert a significant portion of the 45 sites currently assessing its IB imaging software into clien more_horizontal
By Proactive Investors
July 19, 2023
IQ-AI subsidiary Imaging Biometric has bone metastases tech selected by Medical College of Wisconsin
IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF)'s wholly owned subsidiary Imaging Biometrics has had its handheld application IB Nimble selected by the Orthopedic D more_horizontal
By Proactive Investors
July 13, 2023
IQ AI shares surge following promising subsidiary announcement
IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF) surged in early-Thursday trades following a promising update from its subsidiary Imaging Biometrics. Imaging Biometr more_horizontal
By Proactive Investors
July 13, 2023
IQ-AI subsidiary wins orphan drug status for pediatric brain tumour treatment
Imaging Biometrics, a wholly-owned subsidiary of IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF), been has granted orphan drug designation (ODD) status for its oral more_horizontal
By Proactive Investors
June 27, 2023
IQ-AI sent 4% higher following recent successful pre-clinical studies
IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF), the company focused on delivering imaging platforms to treat patients more effectively, enjoyed a boost on the Lond more_horizontal